IMS Health Holdings Inc

IMS Health — William Blair Growth Stock Conference 2015

28 slides from IMS Health's conference presentation, Jun 9, 2015

  1. Slide 1: IMS Health

    Slide 1: IMS Health

    IMS Health Ron Bruehlman SVP & CFO June 9, 2015 IMS Health Confidential. (c) 2015 IMS Health Incorporated. 0 All Rights Reserved.

  2. Slide 2: Legal

    Slide 2: Legal

    Legal Forward-Looking Statements This presentation includes “forward-looking statements.” The words “believes,” “expects,” “may,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-

  3. Slide 3: Who We Are

    Slide 3: Who We Are

    Who We Are Mission Leverage information and technology services to deliver intelligence and drive improved performance for a growing universe of healthcare customers globally Information Technology Services 10+ Petabytes of unique data 55 billion+ transactions per year 1,200+ healthcare informatics

  4. Slide 4: Customers

    Slide 4: Customers

    Customers Med Tech & CH Small & Mid Size Generics --- Segment enhanced by Cegedim 3 IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.

  5. Slide 5: Addressing Customer Needs

    Slide 5: Addressing Customer Needs

    Addressing Customer Needs Supporting mission-critical processes… Research and Pre-launch Launch In market development • Market opportunity • Drug pricing • Market access • Commercial operations assessment optimization • Health technology • Sales force • Clinical trial • Launch readiness assessment e

  6. Slide 6: Addressing Customer Needs

    Slide 6: Addressing Customer Needs

    Addressing Customer Needs …Answering mission-critical questions User Illustrative Questions Sales Which providers generate Does my sales rep drive How much should I pay highest return on rep appropriate prescribing? my sales rep visit? next month? Marketing What share of patients Which underserved I

  7. Slide 7: Addressable Market

    Slide 7: Addressable Market

    Addressable Market $75bn* $5bn $45bn $25bn Information Technology Services Growth Customer Growth Drivers Drivers Expansion • Drug Pipeline • Obsolete IT infrastructure • Consumer Health / OTC • Need for efficiency • Medical devices / • New Data Sources Diagnostics • Data integration • Payers • Emer

  8. Slide 8: Offerings

    Slide 8: Offerings

    Offerings Integrated solutions Information Technology Services • National Audits • Technology & Applications • Work Flow Analytics • Regional Sales Audits • Real World Evidence • Non Biopharma Audits • Consulting • Mobile Intelligence – CRM • OneKey - reference database • Compliance Applications • A

  9. Slide 9: Revenue - Offerings

    Slide 9: Revenue - Offerings

    Revenue - Offerings $mm Information Technology services 2% CAGR 13% CAGR $1,532 $1,521 $1,525 $1,515 $1,488 $1,140 $1,448 $1,126 $1,019 $922 $832 $714 2010 2011 2012 2013 2014 Q1 LTM 2010 2011 2012 2013 2014 Q1 LTM 2015 2015 Dollars at actual foreign exchange rates on GAAP basis. Growth rates at con

  10. Slide 10: Information Solutions

    Slide 10: Information Solutions

    Information Solutions Treatments Medical claims Reference data Mission critical Information Electronic health Prescriptions records Central to our customers’ operations Outcomes Genomics Social media Global gold Stable and Attractive standard sticky economics 5000+ customers 99% customer retention r

  11. Slide 11: Technology Services

    Slide 11: Technology Services

    Technology Services Pre-Integrated Standard Repeatable Information Processes Interoperable Applications Advanced Analytics on Demand Leading CRM Leading Healthcare Franchise Expertise 98 Nexxus customers RWE E360TM Analytics Projects in 80+ leading analytics platform countries each year 43 new Nexxu

  12. Slide 12: Nexxus Application Suite – Case

    Slide 12: Nexxus Application Suite – Case

    Nexxus Application Suite – Case IMS One Data Integration Interoperable Application On-site Analytics Support Solution Suite Team “This will enable us to better harmonize our Reduced Complexity Cost Savings commercial operations so that we can more effectively coordinate our sales and marketing activ

  13. Slide 13: Revenue and Adjusted EBITDA Growth

    Slide 13: Revenue and Adjusted EBITDA Growth

    Revenue and Adjusted EBITDA Growth $mm Revenue Adjusted EBITDA 6% CAGR 10% CAGR $2,544 $2,641 $2,628 $878 $877 $2,443 $829 $2,364 $764 $2,162 $721 $620 2010 2011 2012 2013 2014 Q1 LTM 2010 2011 2012 2013 2014 Q1 LTM 2015 2015 Dollars are actual foreign exchange rates. Adjusted EBITDA is defined in t

  14. Slide 14: Margin Performance

    Slide 14: Margin Performance

    Margin Performance Rolling four quarter P&L ratios SG&A % Revenue Adjusted EBITDA % Revenue 35% 30% 25% 20% 2010 2011 2012 2013 2014 2015 SG&A expense includes: Sales, marketing, administration, IT & infrastructure & non capitalized software development. Calculated using constant Fx rates. Adjusted

  15. Slide 15: Operational Excellence

    Slide 15: Operational Excellence

    Operational Excellence In-house Development Capabilities Customer Facing Resources ~75% >50% <33% <30% 2010 Q1 2015 2010 Q1 2015 Offshore Delivery Headcount Process Automation >2,500 >50% <30% <250 2010 Q1 2015 2010 Q1 2015 14 IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Res

  16. Slide 16: Cegedim Integration Opportunity

    Slide 16: Cegedim Integration Opportunity

    Cegedim Integration Opportunity Sales per employee SG&A % of sales 38% $260K 21% $130K Cegedim Core IMS Cegedim Core IMS Overlapping operations Adjusted EBITDA margins 33% 14% Cegedim Core IMS $50 million run-rate savings Calculated using 2014 Full Year figures at Actual Fx rates. IMS and Cegedim fi

  17. Slide 17: Balance Sheet

    Slide 17: Balance Sheet

    Balance Sheet March 2015 Pro $mm March 2015 Dec 2013 Forma Debt (1) $4,269 $3,969 $5,027 Net Debt $3,783 $3,330 $4,298 Gross Leverage Ratio (2) 4.4x 4.5x 6.1x ~50% reduction in interest expense post IPO and IPO refinancing (1) Excludes $67M and $22M of unamortized OID as of December 31, 2013 and Mar

  18. Slide 18: Shareholder Value Creation Roadmap

    Slide 18: Shareholder Value Creation Roadmap

    Shareholder Value Creation Roadmap Return of capital to shareholders Capital Allocation Debt management opportunity Strategy and Operations Complementary and synergistic Cegedim acquisition Value enhancing tuck-in acquisitions Margin expansion Growing opportunity technology Stable core services info

  19. Slide 19: IMS Health

    Slide 19: IMS Health

    = © o) as Y) 2 imshealth

  20. Slide 20: Appendix

    Slide 20: Appendix

    Appendix 19

  21. Slide 21: Net Income to Adjusted EBITDA

    Slide 21: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 2010 – LTM Q1 2015 LTM Q1 $mm 2010 2011 2012 2013 2014 2015 Net (Loss) Income $(202) $111 $(42) $82 $(189) $133 Benefit from income taxes (113) (173) (19) (130) (96) (323) Other loss (income), net 44 7 29 74 276 255 Interest expense 241 276 275 333 221 169 Interest inco

  22. Slide 22: Net Income to Adjusted EBITDA

    Slide 22: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 1st Quarter 1st Quarter $mm 2015 2014 Net Income (Loss) $298 $(24) Benefit from income taxes (240) (13) Other (income) loss, net (4) 17 Interest expense 37 89 Interest income - (2) Depreciation and amortization 96 107 Deferred revenue purchase accounting adjustments 1 2

  23. Slide 23: Net Income to Adjusted EBITDA

    Slide 23: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 2010 2010 $mm Q1 Q2 Q3 Q4 Full Year Net (Loss) Income $(106) $22 $(78) $(41) $(202) (Benefit from) provision for (56) 13 (68) (2) (113) income taxes Other loss (income), net 71 (77) 98 (48) 44 Interest expense 30 75 77 61 241 Interest income (1) (1) - (1) (1) Depreciati

  24. Slide 24: Net Income to Adjusted EBITDA

    Slide 24: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 2011 2011 $mm Q1 Q2 Q3 Q4 Full Year Net (Loss) Income $(64) $(32) $43 $164 $111 (Benefit from) provision for income (18) (26) 13 (142) (173) taxes Other loss (income), net 66 32 (48) (42) 7 Interest expense 65 73 73 65 276 Interest income - - (1) - (2) Depreciation and

  25. Slide 25: Net Income to Adjusted EBITDA

    Slide 25: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 2012 2012 $mm Q1 Q2 Q3 Q4 Full Year Net Income (Loss) $28 $(21) $4 $(53) $(42) (Benefit from) provision for income (64) 74 (37) 7 (19) taxes Other loss (income), net 31 (74) 36 35 29 Interest expense 68 64 64 79 275 Interest income - - (1) (2) (3) Depreciation and amort

  26. Slide 26: Net Income to Adjusted EBITDA

    Slide 26: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 2013 2013 $mm Q1 Q2 Q3 Q4 Full Year Net Income (Loss) $12 $8 $(20) $82 $82 Provision for (Benefit from) income 5 9 (20) (124) (130) taxes Other (income) loss, net (16) 6 54 30 74 Interest expense 79 75 87 92 333 Interest income (1) (2) (1) (2) (5) Depreciation and amort

  27. Slide 27: Net Income to Adjusted EBITDA

    Slide 27: Net Income to Adjusted EBITDA

    Net Income to Adjusted EBITDA 2014 2014 $mm Q1 Q2 Q3 Q4 Full Year Net (Loss) Income $(24) $(220) $47 $8 $(189) (Benefit from) provision for income (13) (139) 11 45 (96) taxes Other loss (income), net 17 271 (7) (5) 276 Interest expense 89 49 43 40 221 Interest income (2) - (1) (1) (4) Depreciation a

  28. Slide 28: Pro Forma Adjusted EBITDA

    Slide 28: Pro Forma Adjusted EBITDA

    Pro Forma Adjusted EBITDA LTM Q1 2015 Cegedim IMS LTM Total Pro $mm Full Year Q1 2015 Forma 2014* Net Income (Loss) $133 ($268) ($135) (Benefit from) provision for income taxes (323) 15 (308) Other loss, net 255 3 255 Interest expense 169 8 177 Interest income (2) - (2) Depreciation and amortization

Source: Internet Archive copy of s201.q4cdn.com

More decks from IMS Health Holdings Inc